The successful development of an HIV vaccine with novel adjuvants depends on the selection of the most appropriate immunogen-adjuvant formulations. The R-CASA contract, which is focused on HIV vaccine development, will provide an opportunity to develop new approaches to assess optimal HIV immunogens-adjuvants formulations prior to transitioning into clinical trials. R-CASA will 1) generate and propose standardized protocols and endpoint assays for rational and systematic down-screening of HIV immunogen-adjuvant formulations, 2) apply those protocols and assays to screen HIV immunogen-adjuvant formulations, and 3) screen additional immunogens and adjuvants at the direction of NIAID. These efforts will delineate a standardized set of assays for biochemical and immunological characterization of HIV immunogen-adjuvant formulations, down-selection workflow, and go-no-go criteria to maximize the successful transition of immunogen-adjuvant formulations from the pre-clinical testing to First in-Humans (FIH) trials.